Company Profile

Icoria Inc (AKA: Paradigm Genetics Inc )
Profile last edited on: 3/21/2017      CAGE: 3HRH9      UEI: ----------

Business Identifier: Agricultural biotechnology company focused on genomic and functional genomic technologies.
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

108 Alexander Drive
Research Triangle Park, NC 27709
   (919) 425-3000
Location: Single
Congr. District: 04
County: Durham

Public Profile

Previously doing business as Paradigm Gcnetics Inc, in July 2006, Icoria Inc was acquired by Cogenics. The firm operated as Cogenics Icoria, Inc. - subsidiary of Beckman Coulter. Icoria Inc had been a biotechnology company seeking to improve research and development productivity in the agricultural and healthcare industries. The Company used a systems biology approach to understand gene function in the context of biological pathways and to develop assays and biomarkers for molecular diagnostic solutions for life sciences companies. By conducting its research with a gene-to-cell-to-system approach, the Company ensured that it has an accurate and complete understanding of biological systems. Paradigm had focusied on five market opportunities: crop traits, crop protection, green biotechnology, predictive toxicology and biomarker discovery. In March 2005, the firm sold assets relating to its agricultural genomics business to Monsanto Company. Icoria then focused on the discovery, development and commercialization of diagnostics and targeted therapeutics in diabetes, obesity, oncology and other areas of unmet medical need. Icoria's proprietary Gene to Cell to SystemTM approach has four major technology components: gene expression profiling, biochemical profiling phenotypic profiling and pathway informatics.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2005 2 NIH $538,985
Project Title: Metabalomics and Pathway Analysis: Urine, Serum and Blood
2005 2 NIH $548,989
Project Title: Metabolomics: Alcohol-Induced Toxicity
2002 1 NIH $100,000
Project Title: Engineering Biosynthesis of Brefeldin A and Its Analogs
1999 2 DOE $824,999
Project Title: Yield Enhancement Through Gene Discovery for Disease Control

Key People / Management

  Heinrich Gugger -- President

  Alan Higgins

  Henry Nowak -- VP/General Counsel

  John Ryals -- Former President/CEO

  Stanley Stasiewicz

  Scott Uknes

  Weiwen Zhang

Company News

There are no news available.